Is ravulizumab the new treatment of choice for atypical hemolytic uremic syndrome (aHUS)?
Sign Up to like & getrecommendations! Published in 2020 at "Kidney international"
DOI: 10.1016/j.kint.2020.03.011
Abstract: Ravulizumab, a new long-acting C5 inhibitor, recently received FDA approval for the treatment of aHUS. Rates of complete thrombotic microangiopathy response were similar to those observed in major eculizumab trials; however, fewer patients in the… read more here.
Keywords: treatment; treatment choice; choice atypical; ravulizumab new ... See more keywords